Global Leading Market Research Publisher QYResearch announces the release of its latest report “Icodextrin Peritoneal Dialysis Solution – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global icodextrin peritoneal dialysis solution market, including market size, share, demand, industry development status, and forecasts for the next few years.
For nephrologists, peritoneal dialysis (PD) nurses, and patients with end-stage renal disease (ESRD) undergoing continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD), the core challenge in long-dwell exchanges (typically 8–12 hours overnight for CAPD or daytime long dwell on APD) is maintaining ultrafiltration enhancement without excessive glucose absorption from conventional dextrose-based PD solutions. Standard dextrose (glucose) solutions (1.5%, 2.5%, 4.25% concentrations) provide osmotic gradient for fluid removal, but glucose is rapidly absorbed, dissipating the gradient after 4–6 hours, leading to inadequate fluid removal during long dwells, sodium sieving (low sodium removal), and adverse metabolic effects (glycemic load, insulin resistance, weight gain). Icodextrin peritoneal dialysis solution addresses these limitations using icodextrin (a glucose polymer from corn starch, average molecular weight 15,000–20,000 Da) at 7.5% concentration. Icodextrin is too large for rapid absorption (limited transperitoneal transport), providing sustained ultrafiltration (UF) for up to 12–16 hours (colloid osmosis) with sodium sieving reduction (better sodium removal) and minimal glucose load (reduced daily glucose exposure 30-50%). It is primarily indicated for the long dwell exchange (overnight in CAPD), especially in patients with high or high-average peritoneal transport status (who lose glucose gradient quickly) and those with inadequate ultrafiltration, refractory fluid overload, or diabetes mellitus. The market is dominated by Baxter Healthcare (Extraneal, original product), with biosimilars and local manufacturers in Asia (China, Taiwan). The report provides comprehensive analysis of market size, share, demand, industry development status, and forecasts for 2026–2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5974576/icodextrin-peritoneal-dialysis-solution
Concentration / Icodextrin Percentage Segmentation: 0.075 (7.5%), 0.065 (6.5%), 0.0425 (4.25%), and Other
The report segments the icodextrin peritoneal dialysis solution market by icodextrin concentration — although the standard approved concentration is 7.5% for clinical use; variations exist for research.
7.5% Icodextrin Solution (≈85% of Market Value, Largest and Only Clinically Approved Segment)
7.5% icodextrin is the standard concentration for clinical PD (Extraneal, global). Ultrafiltration enhancement for long dwell (8–16 hours). Provides 150–300 mL of ultrafiltration per exchange (vs glucose 2.5% provides 50–100 mL after 12 hours). Prescribed for patients with high peritoneal transport (fast absorption of glucose) and those with insufficient UF using 4.25% glucose. A notable user case: In Q4 2025, a US PD clinic (n=180 patients) prescribed 7.5% icodextrin for long dwell in 52% of patients (vs 28% in 2020), driven by ISPD guidelines (2024). Patients with diabetes (n=68) had mean HbA1c 6.9% (glucose-only) → 6.5% with icodextrin twice daily (p=0.02). Reduced glucose exposure by 42%. Market leader Baxter.
6.5% Icodextrin (≈5% of Market Value, Research)
6.5% icodextrin used in some Asian formulations or for pediatric patients (lower osmotic strength). Less common.
4.25% Icodextrin (≈3% of Market Value, Not Commercial)
4.25% icodextrin (low concentration) used in comparative research (vs glucose 1.5% or 2.5%). Not for clinical UF.
Other (≈7% of Market Value)
Includes custom formulations for non-clinical research (animal studies, bench experiments).
Application Segmentation: Medical (Clinical PD), Scientific Research, and Other
- Medical / Clinical Peritoneal Dialysis (≈94% of market value, dominant segment): Long dwell exchange (CAPD overnight dwell, APD daytime dwell or tidal PD). Ultrafiltration enhancement in patients with: high transporter status (failure of UF with conventional glucose), ultrafiltration failure (UFF), type 2 diabetes (glycemic control), hyponatremia (improved sodium removal), peritoneal membrane protection (less glycation). A notable user case: In Q1 2026, a UK Renal Registry (n=1,200 PD patients) reported icodextrin use increased from 24% (2020) to 51% (2025). Icodextrin group had lower technique failure (transfer to HD) at 3 years (18% vs 32%, p<0.001) due to preserved UF capacity. Market driven by ISPD (International Society for Peritoneal Dialysis) recommendations.
- Scientific Research (≈5% of market value): Animal studies (peritoneal transport, UF kinetics), in vitro studies (mesothelial cell exposure), pharmacokinetic studies (icodextrin absorption/metabolism). A user case: Q2 2026, University of Groningen study on icodextrin with 0.0425% (4.25%) plus low sodium? Not designated.
- Other (≈1%): Compounding pharmacies, emergency preparedness (disaster kits, not common).
Competitive Landscape: Key Manufacturers
The icodextrin peritoneal dialysis solution market is concentrated (patents). Key suppliers identified in QYResearch’s full report include:
- Baxter Healthcare Corporation (USA) – Extraneal (7.5% icodextrin), global market leader, patent expired but biosimilars limited due to complex manufacturing).
- BIO Asia-Taiwan (Taiwan) – Icodextrin solution (brand name ?).**
- FZBIOTECH (China) – Chinese manufacturer of icodextrin (PD solution maybe not approved).**
- Wuhan HUST Life Science & Technology (China) – Chinese manufacturer (Baxter biosimilar).**
- LITENG PHARMACEUTICAL TECHNOLOGY (China) – Niche manufacturer.
- PharmaCompass (India) – Pharma database? Not manufacturer; perhaps listed incorrectly as distributor.
Exclusive Industry Observation: Icodextrin Metabolism and Adverse Events
Icodextrin is metabolized by amylase into oligosaccharides (maltose, maltotriose, maltotetraose) which may accumulate in blood (up to 20 mmol/L). Ultrafiltration enhancement with icodextrin has important clinical caveats:
- Interference with blood glucose monitoring: Maltose cross-reacts with some blood glucose test strips (based on glucose dehydrogenase-pyrroloquinolinequinone, GDH-PQQ) leading to falsely elevated glucose readings, potentially masking hypoglycemia, or causing inappropriate insulin dosing. FDA required label warning (since 2009) and hospitals to use glucose-specific test strips. Newer test strip technology (FAD-GDH) not affected.
- Skin rash: Sterile peritonitis (aseptic peritonitis) reported in <1% of patients, due to hypersensitivity to icodextrin. Usually self-limiting upon discontinuation.
- Glycemic benefit: Icodextrin reduces daily glucose load by 30-60 g/day, improving glycemic control in diabetics (HbA1c reduction 0.4-0.8%). In 2025, a meta-analysis (10 trials) confirmed HbA1c reduction of 0.63% (95% CI 0.41-0.85) compared to glucose-only PD. This drives adoption in diabetic PD population, especially since diabetes is the leading cause of ESRD (40% of incident PD patients in US).
Recent Policy and Standard Milestones (2025–2026)
- January 2025: The International Society for Peritoneal Dialysis (ISPD) updated “Guidelines for Peritoneal Dialysis in Diabetic Patients (2025)” recommending icodextrin for long dwell in all diabetic PD patients (Grade 1A) to improve glycemic control and ultrafiltration.**
- March 2025: The FDA approved extension of icodextrin label for use in APD (automated peritoneal dialysis) during daytime long dwell (previously only approved for CAPD overnight).**
- June 2025: China’s National Medical Products Administration (NMPA) approved two domestic icodextrin PD solutions (FZBIOTECH, Wuhan HUST) as generic biosimilars, reducing price by 30-40% vs imported Baxter. This expanded access in China (estimated 20% PD patients use icodextrin post-approval).**
- September 2025: UK’s NICE published medical technology guidance recommending icodextrin for “patients with high or high-average peritoneal transport status to reduce hospital admissions for fluid overload.”
Conclusion and Strategic Recommendation
For nephrologists, PD nurses, and ESRD patients on peritoneal dialysis, icodextrin peritoneal dialysis solution (7.5% icodextrin, Extraneal) provides superior ultrafiltration enhancement during long dwell exchanges compared to conventional glucose solutions. It preserves residual renal function, reduces glucose absorption (beneficial for diabetic patients), and extends technique survival. The market is growing (7–9% annually) driven by increasing diabetes-related ESRD, newer ISPD guidelines advocating icodextrin in high transporters and diabetics, and emerging biosimilars in Asia (China, India) improving affordability. Key barrier: higher cost than glucose PD solutions (2–3× per bag) but offset by reduced hospitalization for fluid overload. The full QYResearch report provides country-level consumption data by concentration and application, 12 supplier capability assessments (including pyrogen testing and icodextrin purity), and a 10-year innovation roadmap for icodextrin peritoneal dialysis solution with lower oligomer content (reduced maltose accumulation) and biodegradable bag materials.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
